RNA m5C oxidation by TET2 regulates chromatin state and leukaemogenesis
Mutation of tet methylcytosine dioxygenase 2 (encoded by TET2) drives myeloid malignancy initiation and progression<sup>1-3</sup>. TET2 deficiency is known to cause a globally opened chromatin state and activation of genes contributing to aberrant haematopoietic stem cell self-renewal<sup>4,5</sup>. However, the open chromatin observed in TET2-deficient mouse embryonic stem cells, leukaemic cells and haematopoietic stem and progenitor cells<sup>5</sup> is inconsistent with the designated role of DNA 5-methylcytosine oxidation of TET2. Here we show that chromatin-associated retrotransposon RNA 5-methylcytosine (m<sup>5</sup>C) can be recognized by the methyl-CpG-binding-domain protein MBD6, which guides deubiquitination of nearby monoubiquitinated Lys119 of histone H2A (H2AK119ub) to promote an open chromatin state. TET2 oxidizes m<sup>5</sup>C and antagonizes this MBD6-dependent H2AK119ub deubiquitination. TET2 depletion thereby leads to globally decreased H2AK119ub, more open chromatin and increased transcription in stem cells. TET2-mutant human leukaemia becomes dependent on this gene activation pathway, with MBD6 depletion selectively blocking proliferation of TET2-mutant leukaemic cells and largely reversing the haematopoiesis defects caused by Tet2 loss in mouse models. Together, our findings reveal a chromatin regulation pathway by TET2 through retrotransposon RNA m<sup>5</sup>C oxidation and identify the downstream MBD6 protein as a feasible target for developing therapies specific against TET2 mutant malignancies.
Authors
- Xianbin Yu (ORCID: https://orcid.org/0000-0002-7508-8006)
- Qing Dai (ORCID: https://orcid.org/0000-0002-8578-1568)
- Mingjiang Xu (ORCID: https://orcid.org/0000-0002-7063-6253)
- Hao Wang (ORCID: https://orcid.org/0000-0003-4909-8937)
- Juyeong Hong (ORCID: https://orcid.org/0000-0001-6383-8474)
- Yiding Wang (ORCID: https://orcid.org/0000-0002-7172-8651)
- Yu Xiao (ORCID: https://orcid.org/0000-0003-2518-9594)
- Zhongyu Zou (ORCID: https://orcid.org/0000-0001-7152-5435)
- Qinzhe Liu (ORCID: https://orcid.org/0000-0002-3178-590X)
- Boyang Gao (ORCID: https://orcid.org/0000-0002-6956-1450)
- Xiaoyang Dou (ORCID: https://orcid.org/0000-0003-3742-1813)
- Chuan He (ORCID: https://orcid.org/0000-0003-4319-7424)
- Ying Li (ORCID: https://orcid.org/0000-0002-3308-906X)
- Zijie Zhang (ORCID: https://orcid.org/0000-0002-4900-506X)
- Chenxi Sun (ORCID: https://orcid.org/0009-0000-7849-976X)
- Feng‐Chun Yang (ORCID: https://orcid.org/0000-0001-8524-4095)
- Lijie Zhao (ORCID: https://orcid.org/0000-0001-7944-5739)
- Juan Wang (ORCID: https://orcid.org/0000-0002-2531-2188)
Institutions
- Howard Hughes Medical Institute (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of Chicago (US)
Publication Details
- Journal
- Nature
- Published
- 2024-10-02
- DOI
- https://doi.org/10.1038/s41586-024-07969-x
- Citations
- 67
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 15.43